3/5Avidity Biosciences, Inc. (RNA): Auditor change

Market data

Price before filing: n/a (n/a close, split/dividend-adjusted)
Market cap at flag: n/a · Latest: $131.2M (2026-10-16)

What happened next

Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.

Verified excerpt

"As a result of this process, on April 25, 2025, the Audit Committee approved the appointment of Deloitte & Touche LLP ("Deloitte") as the Company's independent registered public accounting firm for the year ending December 31, 2025, with such appointment to be effective immediately following the filing of the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2025 (the "Q1 Form 10-Q")."

Quoted from the filing. Source

What this means

The company changed its outside auditor (8-K Item 4.01). A dismissal or resignation, especially near an annual report or with reported disagreements, is a warning sign. Changes caused by audit firms merging are usually routine.

Type: dismissed
Disagreements reported: no
Former auditor: BDO USA, P.C. · New auditor: Deloitte & Touche LLP